Eli Lilly (NYSE:LLY) said today that the FDA approved its Humalog Junior KwikPen for the treatment of diabetes.
The device is a pre-filled pen with half-unit dosing capabilities, which Eli Lilly said gives patients access to finer dose adjustment.
Get the full story at our sister site, Drug Delivery Business News.
The post Lilly wins FDA nod for Humalog pre-filled Junior KwikPen device appeared first on MassDevice.